CA2672920A1 - Aryl piperazine derivatives useful for the treatment of neuropsychiatric disorders - Google Patents

Aryl piperazine derivatives useful for the treatment of neuropsychiatric disorders Download PDF

Info

Publication number
CA2672920A1
CA2672920A1 CA002672920A CA2672920A CA2672920A1 CA 2672920 A1 CA2672920 A1 CA 2672920A1 CA 002672920 A CA002672920 A CA 002672920A CA 2672920 A CA2672920 A CA 2672920A CA 2672920 A1 CA2672920 A1 CA 2672920A1
Authority
CA
Canada
Prior art keywords
pharmaceutically acceptable
acceptable salt
aryl piperazine
piperazine derivative
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002672920A
Other languages
English (en)
French (fr)
Inventor
Giuseppe Campiani
Stefania Butini
Caterina Fattorusso
Silvia Franceschini
Zia Irene Thale
Karin Sandager Nielsen
Jorgen Scheel-Krueger
Lars Siim Madsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Siena
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2672920A1 publication Critical patent/CA2672920A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Reproductive Health (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
CA002672920A 2006-10-13 2007-10-12 Aryl piperazine derivatives useful for the treatment of neuropsychiatric disorders Abandoned CA2672920A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US85131006P 2006-10-13 2006-10-13
DKPA200601328 2006-10-13
DKPA200601328 2006-10-13
US60/851,310 2006-10-13
PCT/EP2007/060888 WO2008043839A1 (en) 2006-10-13 2007-10-12 Aryl piperazine derivatives useful for the treatment of neuropsychiatry disorders

Publications (1)

Publication Number Publication Date
CA2672920A1 true CA2672920A1 (en) 2008-04-17

Family

ID=38896827

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002672920A Abandoned CA2672920A1 (en) 2006-10-13 2007-10-12 Aryl piperazine derivatives useful for the treatment of neuropsychiatric disorders

Country Status (7)

Country Link
US (1) US20100087445A1 (https=)
EP (1) EP2081907B1 (https=)
JP (1) JP2010505919A (https=)
AU (1) AU2007306274A1 (https=)
CA (1) CA2672920A1 (https=)
MX (1) MX2009003390A (https=)
WO (1) WO2008043839A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2238125A1 (en) * 2008-02-01 2010-10-13 NeuroSearch A/S Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors
WO2010040808A1 (en) * 2008-10-10 2010-04-15 Neurosearch A/S Novel quinolinylamide derivatives useful as modulators of dopamine and serotonin receptors
WO2012047140A1 (en) 2010-10-07 2012-04-12 Telefonaktiebolaget L M Ericsson (Publ) Time slot sharing in tdma communication system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4803203A (en) 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
CA2593266A1 (en) * 2005-01-03 2006-07-13 Universita Degli Studi Di Siena Aryl piperazine derivatives for the treatment of neuropsychiatric disorders

Also Published As

Publication number Publication date
AU2007306274A1 (en) 2008-04-17
JP2010505919A (ja) 2010-02-25
EP2081907B1 (en) 2011-01-26
WO2008043839A1 (en) 2008-04-17
EP2081907A1 (en) 2009-07-29
MX2009003390A (es) 2009-04-09
US20100087445A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
CN1060775C (zh) 用作神经递质重摄取抑制剂的稠合莨菪烷衍生物
CN1910154B (zh) 用作分枝杆菌抑制剂的喹啉衍生物
TWI224102B (en) Serotonergic agents
CN1347414A (zh) 对多巴胺d3受体具有亲和力的三唑化合物
JPH09291034A (ja) 縮合ピリジン化合物およびその医薬としての用途
JP2023554282A (ja) 置換ピペリジノ化合物及び関連する治療方法
TW201111383A (en) Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10
KR20020089372A (ko) 알파-2 길항제로서의 퀴놀린 유도체
CN1387512A (zh) 烟碱性受体激动剂的正调节剂
JP2008543782A (ja) ５−ｈｔ１ａ受容体のピペラジン−ピペリジンアンタゴニストおよびアゴニスト
CA2672920A1 (en) Aryl piperazine derivatives useful for the treatment of neuropsychiatric disorders
CN101712675B (zh) 苯并含氮杂环衍生物及其在治疗神经精神疾病药物的应用
US11485734B2 (en) Beta-carbolines as positive allosteric modulators of the human serotonin receptor 2C (5-HT2C)
JP2000510860A (ja) 抗精神病薬としてのヘキサヒドロ―ピリド（４，３―ｂ）インドール誘導体
CN102869665B (zh) 苯并氮杂环庚三烯化合物
EP1366044B1 (en) 8-{4-[3-(5-fluoro-1h-indol-3-yl)propyl ]-1-piperazinyl} -2-methyl-2h-1, 4-benzoxazin-3(4h)-one methanesulfonate with high affinity for the dopamine d2 receptor and the serotonin reuptake site
US20110085978A1 (en) Novel quinolinylamide derivatives useful as modulators of dopamine and serotonin receptors
JPH11510816A (ja) ＣＮＳ活性を有する４，５―ジヒドロナフト〔１，２―ｃ〕イソキサゾールおよびその誘導体
TW520370B (en) Benzooxazole derivatives and a pharmaceutical composition containing the derivatives as an active ingredient
JPH08508466A (ja) ドーパミンｄ４リガンドとしてのキノロン誘導体
US20110059019A1 (en) Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors
TW201215607A (en) Aryl-and heteroarylamid derivatives as PDE10A enzyme inhibitor
CA2122290A1 (fr) Composes pyrrolopyraziniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
JP2010505919A5 (https=)
JP2002504125A (ja) ドーパミンｄ▲下４▼リガンドとしての２−アミノアルキルアミノキノリン

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20121012